New England Journal of Medicine· 2014Q1· Clinical trial

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

Stephen M. Ansell, Alexander M. Lesokhin, Ivan Borrello, Ahmad Halwani et al.

3,562citations
Q1SCImago
2014year

Short summary

Nivolumab, a PD-1 blocking antibody, demonstrated substantial therapeutic activity in heavily pre-treated patients with relapsed or refractory Hodgkin's lymphoma, achieving an objective response rate of 87%.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Pathology and Forensic Medicine

Pathology and Forensic MedicineMedicine